Evidence map›Paper›PMID 29274022›Full record

Trial reportInternational ophthalmology2019

Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.

Francesco Pichi, Ahmed Mohammed Elbarky, Tarek Roshdy Elhamaky

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Francesco PichiEye Institute, Cleveland Clinic Abu Dhabi, PO Box 112412, Al Maryiah Island, Abu Dhabi, UAE. ilmiticopicchio@gmail.com.ORCID http://orcid.org/0000-0002-7357-4166
Ahmed Mohammed ElbarkyFaculty of Medicine, Benha University, Banha, Egypt.
Tarek Roshdy ElhamakyFaculty of Medicine, Benha University, Banha, Egypt.
Benha University · EGCleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the efficacy of a modified PRN treatment regimen ("treat and monitor") of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.

methodsSeventy eyes of 70 patients with treatment naïve branch retinal vein occlusion were enrolled. All patients underwent a comprehensive ophthalmic examination, spectral-domain optical coherence tomography, and fluorescein angiography. Patients were randomized 1:1 to receive intravitreal aflibercept (34 eyes) and ranibizumab (36 eyes) with a "treat and monitor" treatment regimen with monthly follow-up for 12 months. Primary outcome measures included mean change in best corrected visual acuity (BCVA) and central foveal thickness (CFT) at month 12 compared to baseline.

resultsAt 12 months follow-up, the mean BCVA improved from 0.58 ± 0.13 to 0.20 ± 0.15 logMAR (P = 0.0003) in the aflibercept group (mean injections 2.6 ± 1.51) and from 0.52 ± 0.11 to 0.21 ± 0.1 logMAR (P = 0.0002) in the ranibizumab group (mean injections 2.8 ± 1.78). No statistical difference between the two groups in terms of the visual acuity gains in eyes with macular edema secondary to non-ischemic BRVO treated with either aflibercept or ranibizumab was observed. Mean CFT reduced from 498 ± 46 to 204 ± 23 µm (P < 0.0001) in the aflibercept group and from 488 ± 31 to 212 ± 29 µm (P < 0.0001) in the ranibizumab group.

conclusion"Treat and monitor" regimen is a real-life effective strategy in improving visual acuity after macular edema from branch vein occlusion and in reducing the number of injections.

Indexed as

Visual AcuityAngiogenesis InhibitorsCorneaDose-Response Relationship, DrugDrug Therapy, CombinationFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMacular EdemaProspective StudiesRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionafliberceptAngiogenesis InhibitorsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAfliberceptIntravitrealMacular edemaNon-ischemic BRVORanibizumab

Identifiers

PMID29274022
OpenAlexW2779687202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.